



Venturepharm Laboratories Limited
萬全科技藥業有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 8225)

3rd Quarterly Report 2007

* for identification only

CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET (“GEM”) OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)

GEM has been established as a market designed to accommodate companies to which a high investment risk may be attached. In particular, companies may list on GEM with neither a track record of profitability nor any obligation to forecast profitability. Furthermore, there may be risk arising out of the emerging nature of companies listed on GEM and the business sectors or countries in which the companies operate. Prospective investors should be aware of the potential risks of investing in such companies and should make decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

The principal means of information dissemination on GEM is publication on the Internet website operated by the Exchange. Listed companies are not generally required to issue paid announcements in gazetted newspapers. Accordingly, prospective investors should note that they need to have access to the GEM website in order to obtain up-to-date information on GEM-listed issuers.

The Stock Exchange takes no responsibility for the contents of this document, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

This report, for which the directors of Venturepharm Laboratories Limited (the “Company”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this report is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this report misleading; (3) all opinions expressed in this report have been arrived at after due and careful consideration and founded on bases and assumptions that are fair and reasonable.



Venturepharm Laboratories Limited

萬全科技藥業有限公司*

(incorporated in the Cayman Islands with limited liability)
(Stock Code: 8225)

The Directors are pleased to announce the unaudited thirdly quarterly results of the Company and its subsidiaries (the “Group”) for the nine months ended 30 September 2007, together with the comparative figures.

FINANCIAL HIGHLIGHTS

1. The Group achieved a turnover of approximately RMB30,469,999 for the nine months ended 30 September 2007, representing an decrease of approximately 23% compared with that of the corresponding period in 2006.
2. The Group accomplished a net profit of approximately RMB3,834,000 for the nine months ended 30 September 2007, representing an decrease of approximately 56% compared with that of the corresponding period in 2006.
3. Basic earning per share amounted to RMB1.07 cents for the nine months ended 30 September 2007.
4. The Directors do not recommend payment of any interim dividend for the nine months ended 30 September 2007.

* for identification only

CONSOLIDATED INCOME STATEMENT

		Unaudited Three months ended 30 September		Unaudited Nine months ended 30 September	
		2007	2006	2007	2006
	Notes	RMB'000	RMB'000	RMB'000	RMB'000
Turnover	3	5,409	15,703	30,469	39,882
Cost of sales		<u>(3,859)</u>	<u>(8,921)</u>	<u>(18,853)</u>	<u>(20,321)</u>
Gross profit		1,550	6,782	11,616	19,561
Other revenue		1,092	1,036	1,979	2,314
Administrative expenses		<u>(4,182)</u>	<u>(4,629)</u>	<u>(8,900)</u>	<u>(12,039)</u>
Profit from operations		(1,541)	3,189	4,694	9,836
Finance costs		<u>(667)</u>	<u>(143)</u>	<u>(886)</u>	<u>(287)</u>
PROFIT BEFORE TAXATION	5	(2,208)	3,188	3,808	9,836
Income tax	6	<u>37</u>	<u>(673)</u>	<u>26</u>	<u>(1,051)</u>
Profit for the year		<u>(2,171)</u>	<u>2,554</u>	<u>3,834</u>	<u>8,785</u>
ATTRIBUTABLE TO:					
Equity holders of the Company		(1,969)	2,515	4,203	8,692
Minority interests		<u>(203)</u>	<u>39</u>	<u>(370)</u>	<u>93</u>
		<u>(2,171)</u>	<u>-</u>	<u>3,834</u>	<u>8,785</u>
Earnings per share (<i>cent</i>)	8				
- basic		(0.60)	0.71	1.07	2.47
- diluted		<u>(0.58)</u>	<u>0.70</u>	<u>1.02</u>	<u>2.44</u>

CONSOLIDATED BALANCE SHEET

		Unaudited 30 September 2007 RMB'000	Audited 31 December 2006 RMB'000
	<i>Notes</i>		
Non-current assets			
Property, plant and equipment	9	5,981	6,762
Available for sales financial assets		–	19,248
Interest in associates	10	3,235	3,235
Unlisted Investment	11	9,396	9,396
New drugs technology	12	7,417	8,107
Total		<u>26,029</u>	<u>46,748</u>
Current assets			
Work-in-progress		53,868	46,934
Trade receivables		18,805	18,023
Other receivables, deposits and prepayments	13	48,609	17,823
Amounts due from related companies		1,366	1,296
Bank balances and cash		93,335	10,221
Total		<u>215,983</u>	<u>94,297</u>
Current liabilities			
Trade payables		309	463
Accruals and other payables		10,606	1,085
Receipt in advance		7,197	5,507
Dividend payable		53	54
Interest-bearing borrowings		0	6,451
Tax payable		4,591	5,349
Total		<u>22,756</u>	<u>18,909</u>
Net current assets		<u>193,227</u>	<u>75,388</u>
Long liabilities	14	<u>93,286</u>	<u>0</u>
Total liabilities		<u>116,042</u>	<u>0</u>
Net assets		<u>125,970</u>	<u>112,136</u>
Capital and reserves			
Share capital		38,160	38,160
Reserves		87,810	80,887
Total equity attributable to equity shareholders of the Company		<u>122,947</u>	<u>119,047</u>
Minority interests		<u>3,023</u>	<u>3,089</u>
Total equity		<u>125,970</u>	<u>122,136</u>

CONDENSED CONSOLIDATED CASH FLOW STATEMENT

	Unaudited	
	Nine months ended 30 September 2007 <i>RMB'000</i>	Six months ended 30 June 2007 <i>RMB'000</i>
Net cash used in operating activities	(10,575)	(5,032)
Net cash used in investing activities	403	(597)
Net cash generated from financing activities	93,286	26
Net decrease in cash and cash equivalents	83,114	(5,603)
Cash and cash equivalents at beginning of the period	10,221	10,221
Cash and cash equivalents at end of the period	<u>93,335</u>	<u>4,618</u>

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Share- based capital	Share- payment reserve	Available- for-sales financial assets reserve	Special reserve	Capital reserve	Statutory reserve	Statutory enterprise fund expansion	Retained earnings	Minority interest	Total
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
At 1 January 2006										
(Restate)	38,160	258	(1,377)	6,039	894	3,612	6,795	48,963	3,054	106,398
Profit for the period	-	-	-	-	-	-	-	8,692	93	8,785
At 30 June 2006	<u>38,160</u>	<u>258</u>	<u>(1,377)</u>	<u>6,039</u>	<u>894</u>	<u>3,612</u>	<u>6,795</u>	<u>57,655</u>	<u>3,147</u>	<u>115,183</u>
At 1 January 2007	38,160	53	(1,032)	6,039	894	3,803	6,986	64,144	3,089	122,136
Profit for the period	-	-	-	-	-	-	-	4,203	(370)	3,834
At 30 September 2007	<u>38,160</u>	<u>53</u>	<u>(1,032)</u>	<u>(6,039)</u>	<u>894</u>	<u>3,803</u>	<u>6,986</u>	<u>68,347</u>	<u>2,719</u>	<u>125,970</u>

NOTES TO THE FINANCIAL STATEMENTS

1. Group reorganization

The Company was incorporated in the Cayman Islands on 21 May 2002 as an exempted company with limited liability under the Companies Law (2002 Revision) of the Cayman Islands. Its shares have been listed on the GEM of the Stock Exchange since 10 July 2003 (the “Listing Date”).

Pursuant to a group reorganization to rationalize the structure of the Group in preparation for the listing of the Company’s shares on the GEM of the Stock Exchange, the Company became the holding company of the companies now comprising the Group on 31 March 2003 (the “Group Reorganization”).

2. Accounting policies and basis of preparation

The unaudited condensed financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards (HKFRSs), which is a collective term that includes all applicable individual Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards (HKASs), and interpretations (Ints) issued by the Hong Kong Institute of Certified Public Accountants (HKICPA), accounting principles generally accepted in Hong Kong and the disclosure requirements of the Hong Kong Companies Ordinance. In addition, the financial statements comply with the applicable disclosure provisions of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited. The accounting policies adopted are consistent with those followed in the preparation of the Group’s audited consolidated financial statements for the year ended 31 December 2006.

The accounts have been prepared on a consolidated basis and include the financial statements of the Company and its subsidiaries made up to 30 September 2007. The measurement basis used in the preparation of the financial statements is historical cost as modified by the revaluation of certain financial assets and liabilities at fair value.

3. Turnover and revenues

The Group is principally engaged in the research, development and commercialization of drug products. Passing through the transition in 2005, the Group has established a new and wholly full service business model. With this model, the Company can make profits from the research, producing drugs by contract and commercialization by contract. Revenues recognized during the periods were as follows:

	Unaudited		Unaudited	
	Three months ended		Nine months ended	
	30 September		30 September	
	2007	2006	2007	2006
	RMB'000	RMB'000	RMB'000	RMB'000
Turnover				
– Transfer of technology for new drug and new drug development	15	2,330	3,976	10,188
– Contracted pharmaceutical development and clinical research services associated with technology transfer	1,650	4,370	11,889	10,729
– Contracted pharmaceutical development and clinical research services outsourced by customers	3,708	8,401	13,754	17,379
– Royalty income	–	325	600	950
– Active pharmaceutical ingredient	36	277	250	636
	<u>5,409</u>	<u>15,703</u>	<u>30,469</u>	<u>39,882</u>

4. Segment information

No geographical segment analysis is presented as all assets and operations of the Group for the periods are located in the PRC.

No business segment analysis is presented as the operations of the Group for the periods are principally related to pharmaceutical research and development, registration, application and testing.

5. Profit before taxation

Profit before taxation is arrived at after charging the following items:

	Unaudited		Unaudited	
	Three months ended		Nine months ended	
	30 September		30 September	
	2007	2006	2007	2006
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
Depreciation	142	221	475	443
Less: amount capitalized in work-in-progress	0	0	0	0
	<u>142</u>	<u>221</u>	<u>475</u>	<u>443</u>
Provision against the receivables	0	180	0	981
Amortization of intangible assets	102	90	435	181
Finance cost	<u>667</u>	<u>143</u>	<u>886</u>	<u>287</u>

6. Taxation

	Unaudited		Unaudited	
	Three months ended		Nine months ended	
	30 September		30 September	
	2007	2006	2007	2006
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
Company and subsidiaries				
PRC income tax	(37)	272	(26)	378
	<u>(37)</u>	<u>272</u>	<u>(26)</u>	<u>378</u>

No Hong Kong Profits tax has been provided for, as the Group had no estimated assessable profits in Hong Kong for the nine months ended 30 September 2007 (2006: nil). The Company's subsidiaries are subject to PRC income tax on their assessable profits.

7. Dividends

The board does not recommend the payment of any interim dividend for the nine months ended 30 September 2007 (2006: Nil).

8. Earnings per share

The calculation of basic earnings per share for the three and nine months ended 30 September 2007 is based on the unaudited net profit of approximately RMB-2,171,000 and RMB3,834,000 respectively (2006: approximately RMB2,554,000 and RMB8,785,000 respectively), and the weighted average number of approximately 360,000,000 ordinary shares in issue during the period (2006: 360,000,000) .

The calculation of the diluted earnings per share for the three months and nine months ended 30 September 2007 is based on the unaudited net profit of approximately RMB-2,171,000 and RMB3,834,000 respectively (2006: approximately RMB2,554,000 and RMB8,785,000 respectively), and the weighted average of approximately 375,900,000 shares (2006: approximately 375,900,000) (after adjusting for the effect of the outstanding dilutive options under the share option schemes of the Company).

9. Property, plant and equipment

During the period, the Group acquired property, plant and equipment with a carrying value of RMB56,938 (2006: RMB30,940).

10. Investment in associate

	Unaudited Six months ended 30 June	
	2007	2006
	RMB'000	RMB'000
As at 1 January	3,235	3,235
Additions in investment cost	—	—
Disposal of investment	—	—
Share of associates' results	—	—
	<u>3,235</u>	<u>3,235</u>

Details of the Group's associate at 30 June 2007, which is held indirectly by the Company, are as follows:

Name of associate	Assets	Liabilities	Revenue	Profit/ (loss)	Interest held
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Zhejiang Dankong Venturepharm Co. Ltd.	4,966	—	—	—	45%
NovaDerm Inc.	2,000	—	—	—	40%

11. Unlisted investment

	The Group	
	2007	2006
	RMB'000	RMB'000
Unlisted investment		
Outside Hong Kong	<u>9,396</u>	<u>9,396</u>

19% of shares in Hainan Pioneer Pharmaceutical Co., Ltd., were acquired in January 2004.

12. Intangible assets

The intangible assets of the Group represent capitalized development cost for drug products for own commercialization and it is amortized over its estimated useful life of 5 years.

13. Connected and related party transactions

Details of amounts due from related companies are as follows:

Name of company	Unaudited	Audited
	30 September 2007	31 December 2006
	RMB'000	RMB'000
Sanmenxia Sino way Pharmaceutical Co., Ltd ("Sino way Pharmaceutical")	688	760
Venturepharm Inc. ("VP Inc.")	<u>678</u>	<u>536</u>
	<u>1,366</u>	<u>1,296</u>

Notes: (1) Both companies are the subsidiaries of the Company's shareholder.

(2) The amounts are unsecured, interest-free and repayable on demand.

14. Long liabilities

This item refers to the convertible notes issued by the Company and Banque Heritage S.A. (the Subscriber) in the principal amount of CHF15 million (approximately HK\$97,200,000) due 2012.

MANAGEMENT DISCUSSION AND ANALYSIS

Financial review

Since 2006, there are some challenges for the Chinese pharmaceutical industry, with a number of important events and policies affecting the industry dramatically, including Medicare reform and pricing cutting. Despite of those complicated situations, the Group took active measures and used its own leading advantage in the research field to keep the business go further. For the period ended 30 September 2007, the Group achieved a turnover of approximately RMB30,469,999, which represented a decrease of 23% as compared with the turnover of the corresponding period in 2006.

The gross profit margin of the Group was 38% during the period under review compared with that of 44% during the last year. The decrease is mainly because revenues from drug development service of the Group decreased following the business transition strategy. Unless it has the higher gross profit, it will have an impact on revenues and profits. General and administrative expenses decreased by 26% to approximately RMB8,900,000, which mainly benefits from the policy of the Group oriented to the severe cost control. Therefore, administrative expenses can gradually decrease.

For the period ended 30 September 2007, the Group recorded a profit attributable to shareholders amounted to approximately RMB3,834,000, representing an decrease of 56% as compared with that of approximately RMB8,785,000 for the corresponding period in 2006.

Business review

During the past nine months, in consideration of the long-term development, the Group continued to actively follow its business transition strategy from a leading technology transfer provider to a full and integrated pharmaceutical enterprise. The Group was not confused by the short-term interests, but continually extended its product lines and quickly established the market network in order to rapidly grasp the market shares. The Group initially established a full value-added business model of drug development, clinical testing, product line development and royalty commercialization, which improved the Company's abilities of making profits and resisting venture and then made the Company profitable in the future.


Research and development

The Group's portfolio covers 13 major and high growth therapeutic areas such as diabetes, CNS, cardiovascular disease, dermatology, cancer, AIDS, allergy and antibiotics.


The Group's R&D strength still maintains the leading position in the industry. The Group initiated 35 new projects in the past nine months of 2007 and till now has 205 products under development. During the period, the State Food and Drug Administration ("SFDA") granted 285 new Clinical Study Permits ("CSP") to the Group. For the period ended 30 September 2007, the total number of CSPs has climbed to 5 and the total number of MPs climbed to 96. Meanwhile, the Group focused not only on the increase of the business quantity, but on the accumulation of service brand value and quality management. The aim is to be the CRO Company with brand business, quality control and leading technologies.

The graph sets out the total number of CSPs and MPs obtained during the past years:

Clinical Study Permits



Manufacturing Permits



Sales and marketing

During the nine months ended 30 September 2007, the Group successfully signed 65 PDS and VPS contracts amounting to RMB50,602,000, which represented 9.2% increase in term of contract value compared with that of the corresponding period in 2006. And the increase of contract value indicated the Group provided the extra value service for clients in respect of research, development and clinical service.

Meanwhile, the Group continued to invest in building up its marketing capacity and sales network, and launched new drug products under Venturepharm (萬全) brand name into the PRC market.

Patents

The Group continued to place great emphasis on the protection of intellectual property rights during the reporting period. Up to 30 September 2007, the Group had submitted 121 patent applications.

PROSPECTS

To capitalize on the opportunity of the increased demand of global R&D outsourcing market, the company has made best efforts to improve its service capacities and performance in R&D outsourcing service by providing fully integrated pharmaceutical services that include PDS (Pharmaceutical Development Service), API (Active Pharmaceutical Ingredient), CRS (Contract Research Service), RAS (Regulatory Affairs Service), CMS (Contract Manufacturing Service) and CSS (Contract Sales Service).

The Group actively realized the development strategy by combination of self-development and non-self-development.

ISSUE OF CONVERTIBLE NOTES

On 3 September, The Company and the Subscriber successfully issued the Convertible Notes in the principal amount of CHF15 million (approximately HK\$97,200,000) due 2012. The net proceeds from the Convertible Notes of approximately CHF14,550,000 (HK\$94,284,000) will be used for general corporate and working capital purposes and funding possible strategic acquisitions. For the realization of the Company's global long-term plan and the expansion of its business scope, the Company is looking for the pharmaceutical assets to be acquired. The aim is to form the certain scale and field, to strengthen R&D services in the present treatment field, to improve its abilities entering the new treatment field, and to complete its strategy on area expansion for the improvement of delivery. For the period, the Company hasn't finally searched such investment. Without the certain acquisition target currently, the Company will not actually allot revenues to the possible acquisition cases.

DIVIDEND

The Directors have not recommended payment of any interim dividend for the nine months ended 30 September 2007.

MATERIAL ACQUISITION AND DISPOSAL OF SUBSIDIARY AND ASSOCIATED COMPANIES

No material acquisition or material disposal of subsidiaries and associated companies were made by the Group during the reporting period.

CONTINGENT LIABILITIES

As at 30 September 2007, the Group did not have any contingent liabilities.

CHARGE ON ASSETS

As at 30 September 2007, the Group did not have any charge on assets.

LIQUIDITY AND FINANCIAL RESOURCES, GEARING RATIO

The Group has maintained a sound financial position and prudent liquidity risk management so that there were sufficient cash and marketable securities to make the business development possible. As at 30 September 2007, the Group's current assets amounted to about RMB215,983,000, of which approximately RMB93,335,000 was cash and bank deposits. The Group had no bank charge, and was in a good financial state with sufficient cash.

CAPITAL STRUCTURE

There has not been any change to the capital structure of the Company since that date.

FOREIGN EXCHANGE EXPOSURE

During the period under review, the Group's transactions were substantially denominated in Renminbi ("RMB"). The exchange rate between RMB and USD keep rather fixed, so the Directors are of the view that the Group's exposure to foreign currency exchange risk is limited. In addition, the Group closely monitors its foreign currency exposure from time to time and will engage appropriate hedging activities when needed.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S SHARES

The Company or any of its subsidiaries did not purchase, sell or redeem any of the Company's listed shares during the nine months ended 30 September 2007.

DIRECTORS' INTEREST IN SECURITIES

As at 30 September 2007, the interests and short positions of the directors, chief executives of the Group and their associates in the shares, underlying shares or debentures of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO"), which are required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they are taken or deemed to have taken under such provision of the SFO); or (b) pursuant to section 352 of the SFO, to be entered in the register referred to therein; or (c) pursuant to Rules 5.41 to 5.49 of the GEM Listing Rules were as follows:

Long positions in shares and underlying shares of the Company

(1) The Company

Name	Type of interest	Capacity	Number of shares in which interested (other than under equity derivatives)	Number of shares in which interested under physically settled equity derivatives (Note 3)	Total number of shares	Approximate
						percentage of interest
William Xia GUO	Personal	Beneficial owner	9,110,377	7,560,000	16,670,377	4.72
William Xia GUO	Corporate	Interest of a controlled corporation (Note 1)	149,432,583	–	149,432,583	41.51
William Xia GUO	Corporate	Interest of a controlled corporation (Note 2)	15,966,073	–	15,966,073	4.44

Note 1: The controlled corporation, Venturepharm Holdings Inc. is 47.63% directly held by Mr. Guo Xia and 44.94% held by Mr. Guo Xia through Winsland Agents Limited, his wholly and beneficially owned company incorporated in British Virgin Islands.

Note 2: The controlled corporation, Bright Excel Assets Limited, is 100% beneficially owned by Venturepharm Holdings Inc.

Note 3: Various interests of the directors and chief executives pursuant to physically settled equity derivatives are through share options granted under the Pre-IPO share option scheme. Details of which are set forth as follows:

Name	Number of shares in which interested under physically settled equity derivatives as at 20 June 2003 and 30 September 2007	Date of grant	Exercise price
William Xia GUO	7,200,000	20 June 2003	HK\$0.32
William Xia GUO	360,000	2 March 2005	HK\$0.52
William Xia GUO	324,000	10 August 2006	HK\$0.36
William Xia GUO	966,000	10 May 2007	HK\$0.625

Options granted to Mr. William Xia GUO contain a vesting schedule, pursuant to which may be exercise up to 30% of the underlying shares after 31 December 2003, up to another 30% of the underlying shares after 31 December 2004 and the remaining balance after 31 December 2005. These options will expire ten years after the date of grant. All grantees have also undertaken to the Stock Exchange that they will not exercise their options granted under the Pre-IPO share option scheme within the first 12 months from the listing date.

(2) *A subsidiary of the Company – Beijing Dezhong-Venture Pharmaceutical Technology Development Company Limited*

Name	Type of interest	Capital	Capacity contribution on a Sino-foreign co-operative joint venture	Approximate percentage of interest of shareholding in joint venture
William Xia GUO	Corporate	Interest of a controlled Corporation (<i>Note 1</i>)	US\$111,000	12.83

Note 1: The interest is held by Beijing Venturepharm Biotech Pharmaceutical Technology Company Limited, a limited liability company incorporated in the PRC, for which 99% of its shareholding is beneficially held by Mr. William Xia GUO and 1% held by Dr. Maria Xue-mei SONG.

Save as disclosed above, as at 30 September 2007, none of the directors and chief executive had any interests or short positions in any securities of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which are required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they are taken or deemed to have under such provision of the SFO); or (b) pursuant to section 352 of the SFO, to be entered in the register referred to therein; or (c) pursuant to the rules 5.41 to 5.49 of the GEM Listing Rules.

SUBSTANTIAL SHAREHOLDERS

So far as it is known to any directors, chief executives of the Company, as at 30 September 2007, the interests and short positions of persons in the shares and underlying shares of the Company which would fall to be disclosed pursuant to Division 2 and 3 of Part XV of the SFO or which were required, pursuant to section 336 of Part XV of the SFO, to be entered in the register referred to therein were as follows:

Long positions in shares and underlying shares of the Company

Name	Capacity	Number of Shares	Approximate percentage of interest
Venturepharm Holdings Inc. (Note 1)	Beneficial owner	149,432,583	41.51
Venturepharm Holdings Inc. (Note 2)	Interest of a controlled corporation	15,966,073	4.44
Bright Excel Assets Limited (Note 2)	Beneficial owner	15,966,073	4.44
C Tech Fund	Beneficial owner	80,736,558	22.43
William Xia GUO (Notes 1, 2 & 3)	Beneficial owner and interest of controlled corporations	182,069,033	50.57

Note 1: Venturepharm Holdings Inc. is 47.63% directly held by Mr. Guo Xia and 44.94% held by Mr. Guo Xia through Winsland Agent Limited, his wholly and beneficially owned company incorporated in the British Virgin Islands.

Note 2: The controlled corporation, Bright Excel Assets Limited, is 100% beneficially owned by Venturepharm Holdings Inc.

Note 3: Apart from shares held through Venturepharm Holdings Inc., the interest of 16,310,377 shares comprising of 7,200,000 shares and 360,000 shares underlying the options granted to him under the Pre-IPO Share Option Scheme and Share Option Scheme respectively are beneficially owned by Mr. William Xia GUO.

Save as disclosed above, as at 30 September 2007, there was no other persons who recorded in the register of the Company as having interest or short position in the shares or underlying shares of the Company which would fall to be disclosed under Divisions 2 and 3 of Part XV of the SFO or which were required, pursuant to section 336 of Part XV of the SFO, to be entered in the register referred to therein.

SHARE OPTION SCHEMES

1. Pre-IPO Share Option Scheme

Pursuant to the written resolution passed by the shareholder on 31 March 2003, the Company adopted a share option scheme (the “Pre-IPO Share Option Scheme”) in order to recognize and reward the contribution of certain directors, senior management and advisers, the details of which are set out in the paragraph head “Share Option Scheme” in Appendix IV to the Prospectus. As at 20 June 2003, options comprising a total of 11,520,000 underlying shares were granted. As at 30 September 2007, the options outstanding are 11,520,000 and no options granted pursuant to the Pre-IPO Share Option Scheme had been exercised, cancelled or lapsed. Particulars of the outstanding options that had been granted under the Pre-IPO Share Option Scheme as at 30 September 2007 are as follows:

Name of grantees	Period during which the options remain exercisable after the date of grant	Exercise price per shares	Number of underlying shares under the option as at 20.6.2003 and 30.9.2007
William Xia GUO (Notes 1 & 2)	10 years	HK\$0.32	7,200,000
2 other participants (Notes 1 & 2)	10 years	HK\$0.32	2,520,000
1 other participant (Note 3)	10 years	HK\$0.40	1,800,000
			11,520,000

Note 1: Options granted to each of them contain a vesting schedule, pursuant to which may exercise up to 30 per cent of the underlying shares after 31 December 2003, (subject to Note 2), up to another 30 per cent of the underlying shares after 31 December 2004 and the balance after 31 December 2005.

Note 2: Each of the grantees has undertaken to the Stock Exchange that they will not exercise their options granted under the Pre-IPO Share Options Scheme within the first 12 months from the Listing Date.

Note 3: Options granted to an advisor contain a vesting schedule, pursuant to which may exercise up to 30 per cent of the underlying shares after 31 December 2002, up to another 30 per cent of the underlying shares after 31 December 2003 and the balance after 31 December 2004. The respective grantee has undertaken to the Stock Exchange that he will not exercise his options granted under the Pre-IPO Share Options Scheme within the first 6 months from the Listing Date.

2. Share Option Scheme

Pursuant to the written resolutions by the shareholders of the Company on 23 May 2003, the Company adopted a new share option scheme.

As at 2 March 2005, options comprising a total of 4,042,000 underlying shares were granted. As at 30 September 2007, the options outstanding are 1,892,000 and 2,150,000 options granted pursuant to the Share Option Scheme had been cancelled or lapsed. Particulars of the outstanding options which have been granted under the Share Option Scheme as at 30 September 2007 are as follows:

Name of grantees	Period during which the options remain exercisable after the date of grant	Exercise price per shares	Number of underlying shares under the option at 2.3.2005 and 30.9.2007
William Xia GUO	10 years	HK\$0.52	360,000
Other directors	10 years	HK\$0.52	720,000
Other participant	10 years	HK\$0.52	812,000
			<hr/>
			1,892,000
			<hr/> <hr/>

As at 14 December 2005, options comprising a total of 1,098,000 underlying shares were granted. As at 30 September 2007, the options outstanding are 288,000 and 810,000 options granted pursuant to the Share Option Scheme had been cancelled or lapsed. Particulars of the outstanding options which have been granted under the Share Option Scheme as at 30 September 2007 are as follows:

Name of grantees	Period during which the options remain exercisable after the date of grant	Exercise price per shares	Number of underlying shares under the option at 14.12.2005 and 30.6.2007
4 participants	10 years	HK\$0.45	288,000
			<hr/>
			288,000
			<hr/> <hr/>

As at 10 August 2006, options comprising a total of 4,118,400 underlying shares were granted. As at 30 September 2007, the options outstanding are 3,708,000 and 410,400 options granted pursuant to the Share Option Scheme had been cancelled or lapsed. Particulars of the outstanding options which have been granted under the Share Option Scheme as at 30 September 2007 are as follows:

Name of grantees	Period during which the options remain exercisable after the date of grant	Exercise price per shares	Number of underlying shares under the option at 10.8.2006 and 30.6.2007
William Xia GUO	10 years	HK\$0.36	324,000
Other directors	10 years	HK\$0.36	792,000
4 participants	10 years	HK\$0.36	2,592,000
			3,708,000
			3,708,000

As at 10 May 2007, options comprising a total of 7,568,000 underlying shares were granted. As at 30 September 2007, the options outstanding are 7,568,000 and no options granted pursuant to the Share Option Scheme had been exercised, cancelled or lapsed. Particulars of the outstanding options which have been granted under the Share Option Scheme as at 30 September 2007 are as follows:

Name of grantees	Period during which the options remain exercisable after the date of grant	Exercise price per shares	Number of underlying shares under the option at 10.5.2007 and 30.6.2007
William Xia GUO	10 years	HK\$0.625	966,000
Other directors	10 years	HK\$0.625	956,000
Other participants	10 years	HK\$0.625	5,646,000
			7,568,000
			7,568,000

As at 10 August 2007, options comprising a total of 3,600,000 underlying shares were granted. As at 30 September 2007, the options outstanding are 3,600,000 and no options granted pursuant to the Share Option Scheme had been exercised, cancelled or lapsed. Particulars of the outstanding options which have been granted under the Share Option Scheme as at 30 September 2007 are as follows:

Name of grantees	Period during which the options remain exercisable after the date of grant	Exercise price per shares	Number of underlying shares under the option at 10.5.2007 and 30.6.2007
Other participants	10 years	HK\$1.28	3,600,000
			3,600,000

COMPETING INTERESTS

As at 30 September 2007, none of the Directors or the management shareholders of the Company and their respective associates (as defined in the GEM Listing Rules) had any interest in a business that competes or may compete with the business of the Group.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S SHARES

The Company or any of its subsidiaries did not purchase, sell or redeem any of the Company's listed shares during the nine months ended 30 September 2007.

CORPORATE GOVERNANCE

(1) Corporate governance practices

The Company applied the principles and fully complied with the Code Provision as set out in Appendix 15 of the GEM Listing Rules (“CG Code”) with certain deviations save as disclosed in respect of (1) the roles of chairman and chief executive officer and (2) the remuneration committee. The following summarizes the Company’s corporate governance practices and explains deviations, if any, from the CG Code.

(2) Directors’ securities transactions

The Company has adopted the Company Code for Securities Transactions by Directors of Listed Issuers in compliance with the provisions that are set out in the GEM Listing Rules as its own code of conduct for Directors’ dealings of securities since 29 June 2005. Specific enquiries have been made with all Directors and the Directors confirmed that they have complied with the required standard set out in the Company Code in the period from 1 January 2007 to 30 September 2007.

(3) Chairman and chief executive officer

Chairman of the Board is responsible for the leadership and effective running of the Board, and ensures that all keys and appropriate issues are discussed by the Board in a timely and constructive manner.

However, the Chief Executive of the Company has not yet been appointed. Currently, the day-to-day management of the Company’s business is handled by the executive directors and senior management, who take the responsibility to run the Group’s business and to implement the Group’s strategy so as to achieve the overall commercial objectives of the Company.

In order to comply with CG Code, the Directors will discuss the appointment of a Chief Executive Officer as soon as possible.

(4) Board practice and procedures

During the period from the date of listing to 30 September 2007, the Company has been in compliance with the board practices and procedures as set out in Rule 5.34 of the GEM Listing Rules.

(5) Audit committee

The audit committee was established in July 2003 with written terms of reference in compliance with Rules 5.28 to 5.33 of the GEM Listing Rules. The primary duties of the audit committee are to review the Company's annual reports and accounts, half-yearly reports and quarterly reports and internal control system of the Group and provide advice and comments to the Board. The audit committee has three members comprising the three Independent Non-Executive Directors, Mr. WANG Hong Bo, Mr. Paul CONTOMICHALOS and Mr. WU Ming Yu. Mr. WANG Hong Bo is the chairman of the audit committee.

The company's financial statements for the nine months ended 30 September 2007 have been reviewed by the audit committee.

(6) Directors' acknowledgement of their responsibility for the financial statements

The Directors acknowledge that they take full responsibility in the preparation of the financial statements.

By Order of the Board
William Xia Guo
Chairman

Beijing, the PRC, 13 November 2007

Executive Directors:

William Xia GUO
Maria Xuemei SONG

Non-Executive Directors:

FENG Tao
WU Xin
Nathan Xin ZHANG

Independent Non-Executive Directors:

WANG Hong Bo
Paul CONTOMICHALOS
WU Ming Yu